



Supplementary Fig. 1

A




B




Supplementary Fig. 2


A




B



C




D




Supplementary Fig. 3


A



B




B



C

DRUGS	Plasmatic Concentration (μM)
Carboplatin	188
Paclitaxel	0,228

D



Supplementary Fig. 4


A

	IC50 (μM)		
DRUGS	6T_PDO	7T_PDO	10T.PDO
Adagrasib	<i>n.a.</i>	39,21	<i>n.a.</i>
Alpelisib	1,391	6,811	0,17
Buparlisib	<i>n.a.</i>	2,767	<i>n.a.</i>
Gedatolisib	0,1321	0,4216	0,0033
Ipatasertib	<i>n.a.</i>	9,97	<i>n.a.</i>
Olaparib	<i>n.a.</i>	<i>n.a.</i>	10,52
Rigosertib	3,365	76,37	<i>n.a.</i>
Trastuzumab Deruxtecan	<i>n.a.</i>	<i>n.a.</i>	9,56
Volasertib	3,415	<i>n.a.</i>	<i>n.a.</i>


B

DRUGS	Plasmatic concentration (μM)
Adagrasib	1,63
Alpelisib	4,91
Buparlisib	2,8
Gedatolisib	5,8
Ipa tasertib	2,1
Olaparib	17,5
Rigosertib	14,5
Trastuzumab Deruxtecan	0,8
Volasertib	0,92


C




D




E



F




G




ADAGRASIB	IC50 (μM)
H23	0,4265
H2030	0,8075
H1792	0,3190
H358	0,8954


H



I




Supplementary Fig. 5




Supplementary Fig. 6


A



B



Supplementary Fig. 7



Supplementary Fig. 8

